Cilostazol | CAS#73963-72-1 | PDE III Inhibitor

MedKoo Cat#: 317527 | Name: Cilostazol

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cilostazol is a quinolinone-derivative medication used in the alleviation of the symptom of claudication in individuals with peripheral vascular disease. Cilostazol is a phosphodiesterase inhibitor with therapeutic focus on cyclic adenosine monophosphate (cAMP). It inhibits platelet aggregation and is a direct arterial vasodilator. Its main effects are dilation of the arteries supplying blood to the legs and decreasing platelet coagulation. It is under the trade name Pletal.

Chemical Structure

Cilostazol

CAS#73963-72-1

Theoretical Analysis

MedKoo Cat#: 317527

Name: Cilostazol

CAS#: 73963-72-1

Chemical Formula: C23H31ClFN3O5

Exact Mass: 0.0000

Molecular Weight: 483.96

Elemental Analysis: C, 57.08; H, 6.46; Cl, 7.33; F, 3.93; N, 8.68; O, 16.53

Price and Availability

Size	Price	Availability
1g	USD 250.00	2 Weeks
2g	USD 400.00	2 Weeks
5g	USD 750.00	2 Weeks
10g	USD 1,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Cilostazol; Pletal; Pletaal; Cilostazole; Cilostazolum; OPC 13013; OPC13013; OPC-13013; OPC 21; OPC21; OPC-21;

IUPAC/Chemical Name

6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one

InChi Key

RRGUKTPIGVIEKM-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

SMILES Code

C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM.

In vitro activity:

PDE3 inhibitor cilostazol strongly promoted differentiation of primary cultures of rat Schwann cells via a mechanism involving cAMP/exchange protein directly activated by cAMP (Epac) signaling. Co-treatment with cilostazol prevented paclitaxel-induced dedifferentiation of Schwann cell cultures and demyelination in a mixed culture of Schwann cells and dorsal root ganglia neurons. Reference: Neuropharmacology. 2021 May 1;188:108514. https://pubmed.ncbi.nlm.nih.gov/33684416/

In vivo activity:

Wistar rats were treated with Cilo (0.1 g/kg, p.o.) or with a vehicle for 14 days prior to IS/RE, induced by clamping of the superior mesenteric artery for 30 min with subsequent clamp removal for 2 h. In addition to normalizing MDA, iNOS, and NOx, the Cilo (cilostazol) antioxidant power was confirmed by intensifying tissues content of the total antioxidant capacity. With regard to the anti-inflammatory effect, Cilo reduced the effects of TNF-α, IL-6, and ICAM-1, which were reflected in MPO activity. Furthermore, Cilo had an anti-apoptotic attribute demonstrated by enhancing Bcl-2 content and lessening caspase-3 level. Reference: Life Sci. 2021 Feb 1;266:118882. https://pubmed.ncbi.nlm.nih.gov/33310046/

	Solvent	mg/mL	mM
Solubility
	DMSO	38.7	80.05
	DMSO:PBS (pH 7.2) (1:7)	0.1	0.27
	DMF	12.5	25.83
	Ethanol	1.9	3.93

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 483.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Liu CC, Wu CL, Yeh IC, Wu SN, Sze CI, Gean PW. Cilostazol eliminates radiation-resistant glioblastoma by re-evoking big conductance calcium-activated potassium channel activity. Am J Cancer Res. 2021 Apr 15;11(4):1148-1169. PMID: 33948351; PMCID: PMC8085866. 2. Koyanagi M, Imai S, Iwamitsu Y, Matsumoto M, Saigo M, Moriya A, Ogihara T, Nakazato Y, Yonezawa A, Nakagawa S, Nakagawa T, Matsubara K. Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation. Neuropharmacology. 2021 May 1;188:108514. doi: 10.1016/j.neuropharm.2021.108514. Epub 2021 Mar 5. PMID: 33684416. 3. Gendy AM, Amin MM, Al-Mokaddem AK, Abd Ellah MF. Cilostazol mitigates mesenteric ischemia/reperfusion-induced lung lesion: Contribution of PPAR-γ, NF-κB, and STAT3 crosstalk. Life Sci. 2021 Feb 1;266:118882. doi: 10.1016/j.lfs.2020.118882. Epub 2020 Dec 10. PMID: 33310046. 4. Elrashidy RA, Hasan RA. Cilostazol preconditioning alleviates cyclophosphamide-induced cardiotoxicity in male rats: Mechanistic insights into SIRT1 signaling pathway. Life Sci. 2021 Feb 1;266:118822. doi: 10.1016/j.lfs.2020.118822. Epub 2020 Dec 2. PMID: 33275987.

In vitro protocol:

In vivo protocol:

1. Gendy AM, Amin MM, Al-Mokaddem AK, Abd Ellah MF. Cilostazol mitigates mesenteric ischemia/reperfusion-induced lung lesion: Contribution of PPAR-γ, NF-κB, and STAT3 crosstalk. Life Sci. 2021 Feb 1;266:118882. doi: 10.1016/j.lfs.2020.118882. Epub 2020 Dec 10. PMID: 33310046. 2. Elrashidy RA, Hasan RA. Cilostazol preconditioning alleviates cyclophosphamide-induced cardiotoxicity in male rats: Mechanistic insights into SIRT1 signaling pathway. Life Sci. 2021 Feb 1;266:118822. doi: 10.1016/j.lfs.2020.118822. Epub 2020 Dec 2. PMID: 33275987.

1: Takeuchi R, Shinozaki K, Nakanishi T, Tamai I. Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart. Drug Metab Dispos. 2016 Jan;44(1):68-74. doi: 10.1124/dmd.115.066654. Epub 2015 Oct 14. PubMed PMID: 26467765. 2: Ishii H, Aoyama T, Takahashi H, Kumada Y, Kamoi D, Sakakibara T, Umemoto N, Suzuki S, Tanaka A, Ito Y, Murohara T. Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease. J Cardiol. 2016 Feb;67(2):199-204. doi: 10.1016/j.jjcc.2015.05.003. Epub 2015 Jun 11. PubMed PMID: 26074442. 3: Nagai N, Yoshioka C, Ito Y, Funakami Y, Nishikawa H, Kawabata A. Intravenous Administration of Cilostazol Nanoparticles Ameliorates Acute Ischemic Stroke in a Cerebral Ischemia/Reperfusion-Induced Injury Model. Int J Mol Sci. 2015 Dec 9;16(12):29329-44. doi: 10.3390/ijms161226166. PubMed PMID: 26690139; PubMed Central PMCID: PMC4691110. 4: Taiyeb AM, Muhsen-Alanssari SA, Kraemer DC, Ash O, Fajt V, Ridha-Albarzanchi MT. Cilostazol blocks pregnancy in naturally cycling swine: An animal model. Life Sci. 2015 Dec 1;142:92-6. doi: 10.1016/j.lfs.2015.10.017. Epub 2015 Oct 23. PubMed PMID: 26477292. 5: Koh JS, Yi CO, Heo RW, Ahn JW, Park JR, Lee JE, Kim JH, Hwang JY, Roh GS. Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. Free Radic Biol Med. 2015 Dec;89:54-61. doi: 10.1016/j.freeradbiomed.2015.07.016. Epub 2015 Jul 18. PubMed PMID: 26191652. 6: Zhao Z, Li W, Wang X, Chen Y, Li J, Yang W, Cheng L, Liu E, Liu T, Li G. Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs. Anatol J Cardiol. 2015 Dec;15(12):963-9. doi: 10.5152/akd.2014.5962. Epub 2014 Nov 11. PubMed PMID: 25880049. 7: Kim YR, Kim HN, Hong KW, Shin HK, Choi BT. Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. Psychopharmacology (Berl). 2015 Dec 21. [Epub ahead of print] PubMed PMID: 26686236. 8: Takagi T, Imai T, Mishiro K, Ishisaka M, Tsujimoto M, Ito H, Nagashima K, Matsukawa H, Tsuruma K, Shimazawa M, Yoshimura S, Kozawa O, Iwama T, Hara H. Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier. J Cereb Blood Flow Metab. 2015 Dec 1. pii: 0271678X15621499. [Epub ahead of print] PubMed PMID: 26661252. 9: Hermes TA, Macedo AB, Fogaça AR, Moraes LH, de Faria FM, Kido LA, Cagnon VH, Minatel E. Beneficial cilostazol therapeutic effects in mdx dystrophic skeletal muscle. Clin Exp Pharmacol Physiol. 2015 Dec 7. doi: 10.1111/1440-1681.12521. [Epub ahead of print] PubMed PMID: 26639107. 10: Herath SC, Lion T, Klein M, Stenger D, Scheuer C, Holstein JH, Mörsdorf P, Rollmann MF, Pohlemann T, Menger MD, Histing T. Stimulation of angiogenesis by cilostazol accelerates fracture healing in mice. J Orthop Res. 2015 Dec;33(12):1880-7. doi: 10.1002/jor.22967. Epub 2015 Jul 7. PubMed PMID: 26134894. 11: Kim HN, Kim TY, Yoon YH, Koh JY. Pyruvate and cilostazol protect cultured rat cortical pericytes against tissue plasminogen activator (tPA)-induced cell death. Brain Res. 2015 Dec 2;1628(Pt B):317-26. doi: 10.1016/j.brainres.2015.06.022. Epub 2015 Jun 23. PubMed PMID: 26111647. 12: Galyfos G, Geropapas G, Sigala F, Aggeli K, Sianou A, Filis K. Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting. J Endovasc Ther. 2015 Nov 30. pii: 1526602815619409. [Epub ahead of print] PubMed PMID: 26620397. 13: Zou Y, Hu C, Ye W, Fan L, Xu L, Zhang A. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy after drug-eluting stent implantation in coronary arteries: A meta-analysis of randomized controlled trials. Thromb Res. 2015 Nov;136(5):870-7. doi: 10.1016/j.thromres.2015.08.018. Epub 2015 Aug 29. PubMed PMID: 26342401. 14: Jeon BH, Lee YH, Yun MR, Kim SH, Lee BW, Kang ES, Lee HC, Cha BS. Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis. Metabolism. 2015 Nov;64(11):1444-53. doi: 10.1016/j.metabol.2015.07.014. Epub 2015 Jul 26. PubMed PMID: 26362727. 15: Shiga T, Sahara H, Orito K. Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. Pharmacology. 2015 Nov;96(5-6):210-6. doi: 10.1159/000439090. Epub 2015 Sep 1. PubMed PMID: 26329263. 16: Park SY, Lee SW, Kim HY, Lee SY, Lee WS, Hong KW, Kim CD. Suppression of RANKL-induced osteoclast differentiation by cilostazol via SIRT1-induced RANK inhibition. Biochim Biophys Acta. 2015 Oct;1852(10 Pt A):2137-44. doi: 10.1016/j.bbadis.2015.07.007. Epub 2015 Jul 11. PubMed PMID: 26170060. 17: Takaguri A, Morimoto M, Imai SI, Satoh K. Cilostazol inhibits interleukin-1-induced ADAM17 expression through cAMP independent signaling in vascular smooth muscle cells. Cell Biol Int. 2015 Oct 30. doi: 10.1002/cbin.10559. [Epub ahead of print] PubMed PMID: 26514426. 18: Kim HS, Lim Y, Oh M, Ghim JL, Kim EY, Kim DH, Shin JG. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. Br J Clin Pharmacol. 2015 Oct 1. doi: 10.1111/bcp.12794. [Epub ahead of print] PubMed PMID: 26426352. 19: Jutasompakorn P, Kongpatanakul S, Pongnarin P, Sathirakul K, Chatsiricharoenkul S. Comparative Fasting Bioavailability of 2 Cilostazol Formulations in Healthy Thai Volunteers: An Open-Label, Single-Dose, Randomized, 2-Way Crossover Study. J Med Assoc Thai. 2015 Sep;98(9):910-5. PubMed PMID: 26591403. 20: Tara S, Kurobe H, de Dios Ruiz Rosado J, Best CA, Shoji T, Mahler N, Yi T, Lee YU, Sugiura T, Hibino N, Partida-Sanchez S, Breuer CK, Shinoka T. Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model. Arterioscler Thromb Vasc Biol. 2015 Sep;35(9):2003-10. doi: 10.1161/ATVBAHA.115.306027. Epub 2015 Jul 16. PubMed PMID: 26183618; PubMed Central PMCID: PMC4548543.

View History

Description:

Chemical Structure

Theoretical Analysis

Price and Availability

Preparing Stock Solutions

View History

UBP141

D-Mannuronic Acid

Dac 5945

Yangambin

Y-20811, (S)-

JANEX-1-M

Error message: